<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="bioavailability, and resistance in immunocompromised persons [22]. The nucleoside analogues" exact="acyclovir" post="and ganciclovir are the standard therapy for HHV-1 and"/>
 <result pre="resistance in immunocompromised persons [22]. The nucleoside analogues acyclovir and" exact="ganciclovir" post="are the standard therapy for HHV-1 and CMV, respectively"/>
 <result pre="the viral kinase pUL97 and polymerase pUL54 mediate resistance to" exact="ganciclovir" post="and valganciclovir [25]. The prevalence of resistance against acyclovir"/>
 <result pre="kinase pUL97 and polymerase pUL54 mediate resistance to ganciclovir and" exact="valganciclovir" post="[25]. The prevalence of resistance against acyclovir is 5%"/>
 <result pre="to ganciclovir and valganciclovir [25]. The prevalence of resistance against" exact="acyclovir" post="is 5% in immunocompromised persons and as high as"/>
 <result pre="marrow transplant patients [26], whereas the incidence of resistance to" exact="ganciclovir" post="is 5–10% in organ transplant recipients [27] and 40–50%"/>
 <result pre="or prolonged prophylaxis [25]. HHV-1 strains that are resistant to" exact="acyclovir" post="are typically cross-resistant to thymidine kinase-dependent drugs such as"/>
 <result pre="acyclovir are typically cross-resistant to thymidine kinase-dependent drugs such as" exact="penciclovir" post="and famciclovir. They also may be cross-resistant to polymerase"/>
 <result pre="also may be cross-resistant to polymerase dependent drugs, foscarnet or" exact="cidofovir" post="[26]. Ganciclovir-resistant strains also have shown cross resistance to"/>
 <result pre="also have shown cross resistance to second-line treatments foscarnet and" exact="cidofovir" post="[28]. Targeting the DNA polymerase and thymidine kinase, while"/>
 <result pre="pathogenic virusesAntimicrob. Agents Chemother.2012561135113710.1128/AAC.05908-1122106211 45.Caruso BrownA.E.CohenM.N.TongS.BravermanR.S.RooneyJ.F.GillerR.LevinM.J.Pharmacokinetics and safety of intravenous" exact="cidofovir" post="for life-threatening viral infections in pediatric hematopoietic stem cell"/>
</results>
